Drug Profile
Research programme: ADAPTIR mono-specific therapeutics - Aptevo Therapeutics
Alternative Names: A2M1; ADAPTIR™ mono-specific therapeutics; AH65; anti-CD20 SMIP; DRACO; DRACO anti-CD3 SMIP; ES 301; SMIP - Emergent BioSolutions; SMIPs - Emergent/Pfizer; X1 - Emergent BioSolutionsLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Trubion Pharmaceuticals
- Developer Aptevo Therapeutics
- Class Antibodies; Peptides
- Mechanism of Action CD20 antigen modulators; CD3 antigen inhibitors; Immunosuppressants; T-cell receptor antigen modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
- 31 Mar 2017 Candidates from this research programme are available for licensing as of 31 Mar 2017